We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor.
- Authors
DeFronzo, R. A.; Chilton, R.; Norton, L.; Clarke, G.; Ryder, R. E. J.; Abdul‐Ghani, M.
- Abstract
The recently completed EMPA-REG study showed that empagliflozin significantly decreased the major adverse cardiac events ( MACE) endpoint, which comprised cardiovascular death, non-fatal myocardial infarction ( MI) and stroke, in patients with high-risk type 2 diabetes ( T2DM), primarily through a reduction in cardiovascular death, without a significant decrease in either MI or stroke. In the PROactive study, pioglitazone decreased the MACE endpoint by a similar degree to that observed in the EMPA-REG study, through a marked reduction in both recurrent MI and stroke and a modest reduction in cardiovascular death. These observations suggest that pioglitazone might be an ideal agent to combine with empagliflozin to further reduce cardiovascular events in patients with high-risk diabetes as empagliflozin also promotes salt/water loss and would be expected to offset any fluid retention associated with pioglitazone therapy. In the present paper, we provide an overview of the potential benefits of combined pioglitazone/empagliflozin therapy to prevent cardiovascular events in patients with T2DM.
- Subjects
EMPAGLIFLOZIN; DRUG side effects; MYOCARDIAL infarction; STROKE; TYPE 2 diabetes; CARDIOVASCULAR disease related mortality
- Publication
Diabetes, Obesity & Metabolism, 2016, Vol 18, Issue 5, p454
- ISSN
1462-8902
- Publication type
Article
- DOI
10.1111/dom.12652